Research Article

Correlation of Serum 1,5-AG with Uric Acid in Type 2 Diabetes Mellitus with Different Renal Functions

Kai Zhang, Bizhen Xue, Yuexing Yuan, and Yao Wang

Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Medical School, Southeast University, No. 87 Dingjiaqiao Road, Nanjing 210009, Jiangsu Province, China

Correspondence should be addressed to Yao Wang; jjddhp@126.com

Received 16 June 2018; Revised 1 October 2018; Accepted 14 October 2018; Published 6 March 2019

Aim. Recent studies found that levels of serum uric acid (SUA) were positively associated with serum 1,5-anhydroglucitol (1,5-AG) in subjects with type 2 diabetes mellitus (T2DM). In the current study, we investigated the association between 1,5-AG and UA in T2DM patients with different renal functions.

Methods. A total of 405 T2DM patients, 213 men and 192 women, participated in the study. Patients’ clinical information was collected, and serum 1,5-AG, SUA, and other clinical characteristics were measured. Correlation analyses were carried out to analyze their correlation with serum 1,5-AG and SUA.

Results. The male group showed higher levels of SUA than the female group (282.1 ± 91.2 and 244.7 ± 71.89 μmol/L, respectively, P < 0.01). Pearson’s correlation coefficients determine that SUA was positively associated with 1,5-AG in both men (r = 0.213, P < 0.05) and women (r = 0.223, P < 0.05), and such relationship can be influenced by the renal function. The positive association still existed with moderate impaired renal function. Moreover, 1,5-AG had a negative association with haemoglobin A1c (HbA1c) in T2DM subjects with eGFR ≥ 30 mL/min/1.73 m² (P < 0.01).

Conclusion. The positive association between SUA and 1,5-AG still exists in T2DM with moderate renal failure. 1,5-AG can still reflect the glucose levels in patients with CKD stages 1-3.

1. Introduction

1,5-Anhydroglucitol (1,5-AG), a 1-deoxy form of glucose analog, can reflect blood glucose levels over a period of 3-7 days as well as postprandial glucose [1, 2]. Dietary intake is the main source of 1,5-AG, and the levels of 1,5-AG are stable in healthy individuals [3]. During hyperglycemic periods, the blood glucose level is above the renal threshold and reabsorption of 1,5-AG is thought to be competed with glucose causing a decline in the serum 1,5-AG level [4, 5]. Besides, an earlier study reported that 1,5-AG is not likely to be affected by moderate renal impairment. Moreover, 1,5-AG is still a reliable blood glucose marker in type 2 diabetic patients with chronic kidney disease (CKD) stages 1-3 [6].

Serum uric acid (SUA), a weak organic acid, is the end product of purine metabolism in humans. SUA levels tend to rise with increasing blood glucose levels in the healthy and prediabetes population, while SUA levels decline in a patient with type 2 mellitus (T2DM) [7]. Similar to 1,5-AG, with long-term hyperglycemia, reabsorption of UA is also restricted causing a decrease in the SUA concentrations [8]. A previous study demonstrated that SUA was positively associated with 1,5-AG levels in patients with T2DM [9, 10]. In another research, it was reported that the previously mentioned positive association was stronger in T2DM patients than those without diabetes [11]. However, little information is available on the correlation between SUA and 1,5-AG in T2DM patients with different renal function.

In the current study, therefore, we investigated the correlation between SUA and 1,5-AG using classification by a CKD disease stage in T2DM subjects.

2. Research Design and Methods

2.1. Subjects. In this retrospective study, we enrolled 405 patients that were diagnosed with T2DM [according to guidelines of the World Health Organization (WHO) in 1999] and treated from January 2013 to December 2015.
in the Endocrinology and Metabolism Department of South-

east University-Affiliated Zhongda Hospital. Patients with
cancer, liver dysfunction, or other illnesses affecting renal
function such as renal artery stenosis were excluded, and
patients using drugs like UA-lowering agents, diuretics, or
fructose that might influence the level of UA were excluded.
Type 1 diabetes and mitochondrial diabetes were excluded
by clinical and immunological criteria.

2.2. Clinical and Biochemical Information. We collected
patients’ information: medication use, duration of diabetes,
body mass index (BMI), blood pressure, and so on. More-
over, we sampled blood samples from all subjects between
7:00 and 9:00 a.m. and tested the serum concentrations of
UA, creatinine, TC, TG, LDL, and HDL (Roche Diagnostic
GmbH, Mannheim, Germany). Fasting blood glucose
(FBG) and HbA1c were measured with an automated ana-
alyzer (Kyoto, Japan). 1,5-AG was estimated by using the
GlycoMark assay (Tomen America, USA). Estimated glo-
merular filtration rate (eGFR) was calculated by the Modi-
died Diet in Renal Disease (MDRD) study equation for the
Chinese diabetic population as follows: eGFR = 1.211 × 170
sCr−0.999 × age−0.176 × BUN−0.170 × Alb0.318 × 0.762
(female)
[12, 13]. Subjects with eGFR > 90 mL/min/1.73 m² were cat-
erized under stage 1 (normal kidney function), 60-89 mL/
min/1.73 m² under stage 2 (mild renal failure), 30-59 mL/
min/1.73 m² under stage 3 (moderate renal failure), and
15-29 mL/min/1.73 m² under stage 4 (severely reduced kid-
ney function). Nearly a quarter of the subjects in our study
were found to have mild to moderate renal impairment
including 62 patients with mild renal failure and 29 patients
with moderate renal failure. Moreover, urine albumin-to-
creatinine ratio (ACR) ≥ 30.0 mg/gCre is a risk factor for
GFR decline and is included in the definition of CKD if it per-
sists for ≥3 months [14, 15]. Therefore, ACR was also cal-
culated for the evaluation of renal function and patients with
ACR 0-29.9 mg/gCre were considered as normoalbuminuria,
30.0-299.9 mg/gCre as microalbuminuria, and ≥ 300 mg/gCre
as macroalbuminuria.

2.3. Statistical Analysis. SPSS Software (version 21, SPSS Inc.,
Chicago, IL, USA) was utilized for the statistical analyses.
Independent t-test, bivariate analysis, and multivariate
regression were conducted to calculate the data. Continuous
data are given as the mean ± SD, and categorical data are
expressed as the percentage. P value < 0.05 was considered
statistically significant.

3. Results

3.1. Subjects’ Characteristics. The general clinical data gath-
ered for each gender group are presented in Table 1. There
were 192 women (including 71 premenopausal women and
121 postmenopausal women) and 213 men, and the female
participants recruited in this study were older than male
volunteers (62.9 ± 12.1 and 56.9 ± 13.8 years, respectively,
P < 0.01). The male group showed higher levels of SA than
the female group (282.1 ± 91.2 and 244.7 ± 71.89 μmol/L,
respectively, P < 0.01), while eGFR, ACR, and serum 1,5-
AG levels had no significant difference. Moreover, SA levels
among women with menopause were higher than those
among premenopausal women (234.7 ± 66.57 and 247.9 ±
73.4 μmol/L, respectively) (Table S1).

3.2. Correlations among the 1,5-AG Level and Other Clinical
Variables. With an increase of 1,5-AG concentration, the
glycemic levels like FPG and HbA1c significantly decreased and
SA levels were significantly elevated (Table 2). Therefore,
we identified the correlations between serum 1,5-AG level
and other clinical characteristics: age, HbA1c, and so on
(Table 3). In both groups, 1,5-AG was significantly positively
related with the duration of diabetes (P = 0.016 in female and
P = 0.039 in male), UA (P = 0.038 in female and P = 0.03 in
male), and HbA1c (P < 0.01 in both genders). In addition,
as shown in Figure 1, Pearson’s correlation coefficient
revealed that 1,5-AG was positively associated with UA in
each gender group (male: r = 0.213, P < 0.05; female: r =
0.223, P < 0.05), and the positive correlation also exists in
premenopausal women (r = 0.256, P < 0.05) and postmeno-
pausal women (r = 0.212, P < 0.05). Nevertheless, in both
groups, there was no significant relationship between 1,5-
AG and BMI or FPG.

3.3. Correlations between Serum 1,5-AG and SA with
Different Renal Functions. Next, we investigated the factors
correlated with the positive association between serum 1,5-
AG and SA. The positive relationship still existed after
adjusting possible influencing factors, such as age, BMI,
blood pressure, lipids, HbA1c, and FPG, by multivariate
regression analysis in both genders (Table 4). Interestingly,
when taking eGFR and ACR into account, the previously
mentioned positive association no longer existed (Table 4).
Therefore, patients were divided into four or three groups
using classification by eGFR or ACR in T2DM subjects.
As indicated in Table 5 and Table S2, the association
between SA and 1,5-AG remains significant in diabetic
patients with eGFR > 60 mL/min/1.73 m² (P < 0.05) or with
ACR < 300 mg/gCre (P < 0.01).

3.4. Correlation between 1,5-AG and HbA1c in Different
Renal Functions. Finally, regression analyses were conducted
to investigate the correlation between 1,5-AG and HbA1c in
T2DM with different renal functions. As shown in Table 5,
1,5-AG had a negative association with HbA1c in T2DM
subjects with eGFR ≥ 30 mL/min/1.73 m² (P < 0.01).

4. Discussion

The current study provides the evidence that SA in relation
to 1,5-AG in T2DM subjects with CKD stages 1-2. The rela-
tion was noted in both men and women. Furthermore, the
negative association between HbA1c and 1,5-AG still exists
in T2DM patients with eGFR ≥ 30 mL/min/1.73 m², and
1,5-AG remains a reliable glycemic control marker.

UA is a product of the metabolic breakdown of purine
nucleotides and is excreted and absorbed via the kidney.
When the concentration of blood glucose reaches a kidney’s
reabsorptive threshold, glucose will be excreted in the urine
causing the decline of reabsorption of UA, and any
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TC: total cholesterol; TG: triglycerides.

Table 1: Clinical characteristics of the study participants.

| Characteristics          | Female (n = 192) | Male (n = 213) | P value |
|--------------------------|------------------|----------------|---------|
| Age (years)              | 62.9 ± 12.1      | 56.9 ± 13.8    | <0.001  |
| Diabetes duration (years)| 8.7 ± 6.8        | 6.5 ± 6.1      | <0.001  |
| BMI (kg/m²)              | 24.4 ± 2.9       | 24.6 ± 3.4     | 0.466   |
| SBP (mmHg)               | 133.5 ± 17.1     | 130.8 ± 16     | 0.106   |
| DBP (mmHg)               | 78 ± 8.4         | 79.6 ± 10.2    | 0.083   |
| Serum creatinine (mg/dL) | 0.66 ± 0.19      | 0.82 ± 0.2     | <0.001  |
| Blood urea nitrogen (mg/dL) | 15.4 ± 4.78   | 16.29 ± 4.8    | 0.052   |
| Serum albumin (g/dL)     | 4.4 ± 1.32       | 4.5 ± 1.94     | 0.548   |
| ACR (mg/gCre)            | 54.3 ± 69.46     | 52.56 ± 72.38  | 0.805   |
| eGFR (mL/min/1.73 m²)    | 114.6 ± 31.2     | 115.1 ± 31.8   | 0.873   |
| UA (µmol/L)              | 244.7 ± 71.89    | 282.1 ± 91.2   | <0.001  |
| FBG (mmol/L)             | 9.1 ± 3.5        | 9.2 ± 4.2      | 0.708   |
| 1,5-AG (µg/mL)           | 6.2 ± 6.01       | 6.1 ± 7.2      | 0.881   |
| HbA1C (%)                | 9.18 ± 2.33      | 9.34 ± 2.56    | 0.517   |
| HDL (mmol/L)             | 1.19 ± 0.52      | 1.1 ± 0.51     | 0.081   |
| LDL (mmol/L)             | 2.72 ± 0.99      | 2.54 ± 0.96    | 0.059   |
| TC (mmol/L)              | 4.83 ± 1.1       | 4.61 ± 1.05    | 0.386   |
| TG (mmol/L)              | 1.99 ± 1.3       | 1.97 ± 1.5     | 0.886   |

SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; ACR: urine albumin-to-creatinine ratio; TC: total cholesterol; TG: triglycerides.

Table 2: Comparison of variables according to quartiles of serum 1,5-AG levels.

| Quartiles of 1,5-AG (µg/mL) | <1.45 | 1.45–3.35 | 3.35–8.70 | >8.70 | P value |
|-----------------------------|-------|-----------|-----------|-------|---------|
| Age (years)                 | 56.1 ± 14.3 | 57.6 ± 13.6 | 61.6 ± 11.8 | 63.6 ± 12.3 | <0.001  |
| Diabetes duration (years)   | 6.1 ± 5.6  | 8.1 ± 6.8  | 9.2 ± 7.4  | 6.8 ± 5.7  | 0.003   |
| BMI (kg/m²)                 | 24.84 ± 3.43 | 24.05 ± 3.28 | 24.29 ± 2.61 | 24.93 ± 3.38 | 0.149   |
| SBP (mmHg)                  | 129 ± 13.4 | 130.6 ± 16  | 134.5 ± 17.3 | 134.3 ± 18.5 | 0.041   |
| DBP (mmHg)                  | 78.2 ± 8.9 | 78.8 ± 10.4 | 80.1 ± 9.8  | 78.2 ± 8.6  | 0.422   |
| Serum creatinine (mg/dL)    | 0.7 ± 0.16 | 0.73 ± 0.21 | 0.76 ± 0.26 | 0.79 ± 0.2  | 0.021   |
| Blood urea nitrogen (mg/dL) | 16 ± 4.49  | 16.29 ± 5.06 | 15.45 ± 4.78 | 15.5 ± 4.49 | 0.464   |
| Serum albumin (g/dL)        | 4.3 ± 1.37  | 4.5 ± 1.43  | 4.6 ± 1.52  | 4.3 ± 1.34  | 0.547   |
| ACR (mg/gCre)               | 57.06 ± 70.53 | 54.10 ± 69.27 | 54.60 ± 71.52 | 53.10 ± 68.92 | 0.786   |
| eGFR (mL/min/1.73 m²)       | 117.48 ± 27.17 | 114.32 ± 31.78 | 116.12 ± 35.97 | 110.37 ± 35.15 | 0.442   |
| UA (µmol/L)                 | 233.95 ± 84.88 | 247.91 ± 82.58 | 277.77 ± 83.59 | 296.56 ± 82.96 | <0.001  |
| FBG (mmol/L)                | 12.13 ± 4.27  | 9.43 ± 3.16  | 8.13 ± 3.67  | 6.86 ± 1.84  | <0.001  |
| 1,5-AG (µg/mL)              | 0.96 ± 0.28  | 2.32 ± 0.58  | 5.92 ± 1.53  | 16.63 ± 6.89  | <0.001  |
| HbA1C (%)                   | 11.97 ± 1.99 | 9.97 ± 1.8   | 8.09 ± 1.14  | 7.00 ± 1.11  | <0.001  |
| HDL (mmol/L)                | 1.19 ± 0.39  | 1.17 ± 0.31  | 1.12 ± 0.28  | 1.09 ± 0.29  | 0.157   |
| LDL (mmol/L)                | 2.69 ± 0.71  | 2.78 ± 1.21  | 2.52 ± 0.79  | 2.51 ± 1.10  | 0.140   |
| TC (mmol/L)                 | 4.92 ± 0.98  | 4.83 ± 1.07  | 4.65 ± 1.25  | 4.45 ± 0.92  | 0.180   |
| TG (mmol/L)                 | 2.07 ± 1.64  | 1.92 ± 1.45  | 1.81 ± 1.09  | 1.92 ± 1.31  | 0.616   |

SBP: systolic blood pressure; DBP: diastolic blood pressure; ACR: urine albumin-to-creatinine ratio; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TC: total cholesterol; TG: triglycerides.

Impairment of kidney function can result in hyperuricemia [16–18]. In the present study, SUA levels in the female group are lower compared to those in the male group, which is consistent with previous observations [19–21]. Moreover, in our research, SUA levels of menopause women were also higher than those of premenopausal women. One possible explanation for these results is that estrogens may promote renal clearance of UA. And actually, studies have demonstrated that administration of estrogen therapy to males can decrease SUA levels [22–24]. In addition, the positive relationship...
between SUA and 1.5-AG in the male and female groups has been reported in previous studies; however, little is known about the association in the premenopausal and postmenopausal women. Since hormonal situation may have an influence on the relationship between serum 1,5-AG and UA, we analyzed the relationship of female participants based on hormonal situation. Interestingly, as indicated in Figure S1, the positive correlation still existed in both premenopausal and postmenopausal women. Besides, similar to SUA, 1.5-AG levels of menopause women were also higher than those of premenopausal women. One possible explanation to illustrate the result is that estrogens may also promote renal clearance of 1,5-AG.

Although the positive relation between SUA and 1,5-AG has been found in a large number of studies, little is known about the association in patients with chronic renal disorder. In our present study, multivariate analyses found a positive association between SUA and 1,5-AG, independent of

Table 3: Stepwise multiple linear regression analysis with serum 1,5-AG levels as the dependent variable and clinical characteristics as independent variables.

| Variables                  | Female β  | Female P value | Male β  | Male P value |
|---------------------------|-----------|----------------|---------|--------------|
| Age (years)               | 0.074     | 0.271          | 0.025   | 0.722        |
| Diabetes duration (years) | −0.163    | 0.016          | −0.134  | 0.039        |
| BMI (kg/m²)               | −0.050    | 0.409          | −0.032  | 0.600        |
| SBP (mmHg)                | 0.118     | 0.115          | 0.042   | 0.618        |
| DBP (mmHg)                | −0.119    | 0.088          | −0.022  | 0.792        |
| Serum creatinine (mg/dL)  | −0.071    | 0.432          | −0.057  | 0.436        |
| Blood urea nitrogen (mg/dL)| 0.003    | 0.962          | −0.109  | 0.091        |
| ACR (mg/gCre)             | 0.040     | 0.570          | 0.014   | 0.816        |
| eGFR (mL/min/1.73 m²)     | −0.097    | 0.142          | −0.084  | 0.178        |
| HbA1c (%)                 | −0.528    | <0.001         | −0.563  | <0.001       |
| FBG (mmol/L)              | −0.122    | 0.074          | −0.094  | 0.140        |
| UA (µmol/L)               | 0.143     | 0.038          | 0.148   | 0.030        |
| HDL (mmol/L)              | −0.081    | 0.182          | 0.044   | 0.507        |
| LDL (mmol/L)              | 0.075     | 0.282          | −0.004  | 0.952        |
| TC (mmol/L)               | −0.071    | 0.333          | −0.048  | 0.522        |
| TG (mmol/L)               | 0.019     | 0.870          | −0.080  | 0.246        |

SBP: systolic blood pressure; DBP: diastolic blood pressure; ACR: urine albumin-to-creatinine ratio; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TC: total cholesterol; TG: triglycerides.

Figure 1: The relationship, as shown by Pearson’s correlation coefficient, between levels of serum 1,5-AG and serum UA (a) in men (r = 0.213, P < 0.05) and (b) in women (r = 0.223, P < 0.05).
HbA1c and FBG. Interestingly, when taking eGFR and ACR into account, the significant association mentioned previously disappeared. Therefore, the subjects were classified into different groups based on eGFR or ACR. We found that 1,5-AG and SUA still associated positively in T2DM patients with eGFR ≥ 60 mL/min/1.73 m² or with ACR < 300 mg/gCre. However, this positive association no longer existed when eGFR declined under 60 mL/min or ACR ≥ 300 mg/gCre. Consequently, we suggest that the renal function can affect the association between SUA and 1,5-AG and some explanations may illustrate the results. Firstly, both 1,5-AG and UA were competitively reabsorbed with renal glucose in the proximal tubules [25, 26], and it has been reported that renal disorder can affect UA transport in diabetic patients and 1,5-AG was negatively associated with kidney function [27, 28]. Secondly, a previous study reported that a solute carrier (SLC) 2A9, also a fructose transporter, was identified to be a UA transporter [29]. Moreover, dapagliflozin, a sodium-glucose cotransporter (SGLT2) inhibitor, significantly decreased SUA compared with placebo and might also decrease serum 1,5-AG, indicating that 1,5-AG and UA may share the same renal transporter, and we suppose that impairment of the transporter in patients with moderate renal disorder may result in the disappearance of the positive association between 1,5-AG and SUA [30, 31]. Furthermore, 1,5-AG is positively correlated with SUA in T2DM patients and may share a common renal transporter with UA; therefore, 1,5-AG cannot reflect blood glucose levels accurately in patients who take uricosuric medicine like benzbromarone.

Currently, HbA1C is the "gold standard" for identifying the overall blood glucose control; however, 1,5-AG which can reflect rapid changes in glycemia is more accurate than HbA1C [32]. Therefore, 1,5-AG as a blood glucose marker can provide complementary information to HbA1C. Moreover, in our previous observation, we demonstrated that serum 1,5-AG is a sensitive and specific glycemic control marker and can identify diabetes in populations [33]. However, unlike HbA1C, multiple factors such as diet and renal function may limit the comparison of 1,5-AG levels between individuals. Some researchers reported that 1,5-AG cannot be used to predicate blood glucose in patients that suffer from impaired renal function [34]. In the present study, the subjects were classified into different groups by eGFR, and we found that 1,5-AG was still negatively associated with HbA1c in T2DM subjects with eGFR ≥ 30 mL/min/1.73 m². Considering these results, we conclude that 1,5-AG remain a reliable glycemic control marker even if patients suffer mild or moderate renal dysfunction, which is consistent with a previous observation [35]. In addition, in the current study, we showed that serum 1,5-AG levels were not influenced by eGFR, whereas a previous study reported that 1,5-AG was negatively correlated with kidney function, which might be owing to an age-associated decrease in the renal glucose threshold [28].

The limitations of the present study include the following: our study is a cross-sectional design in a single center with a high risk of selection bias; the consumption of meat or alcohol was not examined, and urate oxidase was not assessed.

Collectively, the present study provides the evidence that 1,5-AG was positively associated with SUA in T2DM patients with mild and moderate renal failure. In addition, 1,5-AG can reflect the glucose metabolic situation in patients with CKD stages 1-3.

### Data Availability

All the data supporting the results are shown in the paper and can be applicable from the corresponding author.
**Ethical Approval**

This study was approved by the Research Ethics Committee of Zhongda Hospital. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

**Consent**

Informed consent was obtained from all individual participants included in the study.

**Conflicts of Interest**

The authors declared that they have no conflict of interest.

**Supplementary Materials**

Supplementary Material Description: clinical characteristics

Consent

The authors declared that they have no conflict of interest.

**References**

[1] X. Ma, Y. Hao, X. Hu et al., “1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with newly diagnosed type 2 diabetes mellitus,” *Diabetes Technology & Therapeutics*, vol. 17, no. 5, pp. 320–326, 2015.

[2] H. Su, X. Ma, J. Yin et al., “Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status,” *Acta Diabetologica*, vol. 54, no. 5, pp. 463–470, 2017.

[3] L. Ying, X. Ma, J. Yin et al., “The metabolism and transport of 1,5-anhydroglucitol in cells,” *Acta Diabetologica*, vol. 55, no. 3, pp. 279–286, 2018.

[4] Y. Akanuma, M. Morita, N. Fukuzawa, T. Yamanouchi, and H. Akanuma, “Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients,” *Diabetologia*, vol. 31, no. 11, pp. 831–835, 1988.

[5] T. Yamanouchi, S. Minoda, M. Yabuuchi et al., “Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients,” *Diabetes*, vol. 38, no. 6, pp. 723–729, 1989.

[6] W. J. Kim, C. Y. Park, K. B. Lee et al., “Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction,” *Diabetes Care*, vol. 35, no. 2, pp. 281–286, 2012.

[7] J. Tuomilehto, P. Zimmet, E. Wolf, R. Taylor, P. Ram, and H. King, “Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji,” *American Journal of Epidemiology*, vol. 127, no. 2, pp. 321–336, 1988.

[8] P. Bandaru and A. Shankar, “Association between serum uric acid levels and diabetes mellitus,” *International Journal of Endocrinology*, vol. 2011, Article ID 604715, 6 pages, 2011.

[9] M. Gotoh, C. Li, M. Yatoh, A. Iguchi, and Y. Hirooka, “Serum uric acid concentrations in type 2 diabetes: its significant relationship to serum 1,5-anhydroglucitol concentrations,” *Endocrine Regulations*, vol. 39, no. 4, pp. 119–125, 2005.

[10] M. Koga, J. Murai, H. Saito et al., “Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system,” *Clinica Chimica Acta*, vol. 410, no. 1-2, pp. 70–73, 2009.

[11] M. Ouchi, K. Oba, J. Aoyama et al., “Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus,” *Clinical Biochemistry*, vol. 46, no. 15, pp. 1436–1441, 2013.

[12] C. F. Kuo, K. H. Yu, Y. M. Shen, and L. C. See, “The Chinese version of the modification of diet in renal disease (MDRD) equation is a superior screening tool for chronic kidney disease among middle-aged Taiwanese than the original MDRD and Cockcroft-Gault equations,” *Biomedical Journal*, vol. 37, no. 6, pp. 398–405, 2014.

[13] Y. C. Ma, L. Zuo, J. H. Chen et al., “Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease,” *Journal of the American Society of Nephrology*, vol. 17, no. 10, pp. 2937–2944, 2006.

[14] A. Levin and P. E. Stevens, “Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward,” *Kidney International*, vol. 85, no. 1, pp. 49–61, 2014.

[15] T. Melsom, M. D. Solbu, J. Schei et al., “Mild albuminuria is a risk factor for faster GFR decline in the nondiabetic population,” *Kidney International Reports*, vol. 3, no. 4, pp. 817–824, 2018.

[16] D. P. Hyink, J. Z. Rappoport, P. D. Wilson, and R. G. Abramson, “Expression of the urate transporter/channel is developmentally regulated in human kidneys,” *American Journal of Physiology Renal Physiology*, vol. 281, no. 5, pp. F875–F886, 2001.

[17] S. Tazawa, T. Yamato, H. Fujikura et al., “SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose,” *Life Sciences*, vol. 76, no. 9, pp. 1039–1050, 2005.

[18] T. Yamanouchi, H. Akanuma, T. Nakamura, I. Akaoka, and Y. Akanuma, “Reduction of plasma 1,5-anhydroglucitol (1-deoxyglucose) concentration in diabetic patients,” *Diabetologia*, vol. 31, no. 1, pp. 41–45, 1988.

[19] F. Mateos Antón, J. García Puig, T. Ramos, P. González, and J. Ordás, “Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17β (E2) on the renal handling of urate,” *Metabolism*, vol. 35, no. 4, pp. 343–348, 1986.

[20] S. Akizuki, “Serum uric acid levels among thirty-four thousand people in Japan,” *Annals of the Rheumatic Diseases*, vol. 41, no. 3, pp. 272–274, 1982.

[21] J. G. Puig, F. A. Mateos, M. E. Miranda et al., “Purine metabolism in women with primary gout,” *The American Journal of Medicine*, vol. 97, no. 4, pp. 332–338, 1994.
[22] A. E. Hak and H. K. Choi, “Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey,” *Arthritis Research & Therapy*, vol. 10, no. 5, p. R116, 2008.

[23] H. Sumino, S. Ichikawa, T. Kanda, T. Nakamura, and T. Sakamaki, “Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricemia,” *The Lancet*, vol. 354, no. 9179, p. 650, 1999.

[24] E. V. Lally, G. Ho Jr, and S. R. Kaplan, “The clinical spectrum of gouty arthritis in women,” *Archives of Internal Medicine*, vol. 146, no. 11, pp. 2221–2225, 1986.

[25] T. Yamanouchi and Y. Akanuma, “Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control,” *Diabetes Research and Clinical Practice*, vol. 24, Supplement, pp. S261–S268, 1994.

[26] T. Yamanouchi, T. Shinohara, N. Ogata, Y. Tachibana, I. Akaoka, and H. Miyashita, “Common reabsorption system of 1,5-anhydro-D-glucitol, fructose, and mannose in rat renal tubule,” *Biochimica et Biophysica Acta (BBA) – General Subjects*, vol. 1291, no. 1, pp. 89–95, 1996.

[27] I. Hisatome, N. Sasaki, M. Yamakawa et al., “Two cases of persistent hypouricemia associated with diabetes mellitus,” *Nephron*, vol. 61, no. 2, pp. 196–199, 1992.

[28] C. Hasslacher and F. Kulozik, “Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: a comparative study with HbA1c and glycated albumin,” *Journal of Diabetes*, vol. 8, no. 5, pp. 712–719, 2016.

[29] A. Enomoto, H. Kimura, A. Chairoungdua et al., “Molecular identification of a renal urate anion exchanger that regulates blood urate levels,” *Nature*, vol. 417, no. 6887, pp. 447–452, 2002.

[30] V. Vitart, I. Rudan, C. Hayward et al., “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout,” *Nature Genetics*, vol. 40, no. 4, pp. 437–442, 2008.

[31] G. Musso, R. Gambino, M. Cassader, and G. Pagano, “A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials,” *Annals of Medicine*, vol. 44, no. 4, pp. 375–393, 2012.

[32] H. Seok, J. H. Huh, H. M. Kim et al., “1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes,” *Diabetes and Metabolism Journal*, vol. 39, no. 2, pp. 164–170, 2015.

[33] Y. Wang, Y. Yuan, Y. Zhang et al., “Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes,” *Acta Diabetologica*, vol. 54, no. 5, pp. 425–431, 2017.

[34] H. Ichikawa, Y. Nagake, M. Takahashi et al., “What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis,” *Nihon Jinzo Gakkai Shi*, vol. 38, no. 7, pp. 305–308, 1996.

[35] Y. Wang, Y. Bai, R. Yang, and Y. Song, “Serum 1,5-anhydroglucitol concentrations remain valid as a glycemic control marker in diabetes with earlier chronic kidney disease stages,” *Experimental and Clinical Endocrinology & Diabetes*, 2017.